PPARG and skin basal cell carcinoma: However, the percentages of positive cells for both M1 and M2 cell surface markers of macrophages treated with BCC-CM in combination with PPARγ agonist rosiglitazone did not substantially change, as revealed by flow cytometry analysis (Figure S2 in Supplementary Material).